Breaking News, Financial News

Financial Report: Catalent

IPO costs impact results

Catalent
 
1Q Revenues: $418.3 million (+1%)
 
1Q Loss: $19.5 million (earnings were $1.5 million in 1Q13)
 
Comments: Revenue from the Oral Technologies segment was $261.1 million, up 1% in the quarter. Revenue from the Development and Clinical Services segment was $103.1 million, up 2%. Revenue from the Medication Delivery Solutions segment was $56.9 million, up 1%. Loss in the quarter was related to one-time IPO costs of $50.4 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters